

# Recruitment and Demographic Characteristics of Patients Approached to Participate in a Randomized Nutraceutical Clinical Trial



<u>Sanjana Perungulam</u>, Richard Dunne, Jihane Jean, Paula Vertino, Beverly Canin, Michael Sohn, Charles Kamen, Michelle Shayne, Jason Zittel, Luke Peppone, Supriya Mohile, Michelle Janelsins, Nikesha Gilmore

## Introduction

- Frailty is a major concern in older adults with cancer
- Older adults are underrepresented in clinical trials
- Frailty interventions are needed
- Better recruitment strategies for older adults are needed

#### **OBJECTIVE:**

To identify barriers and facilitators to participation in supportive cancer trials for older adults

# Methods

- We identified reasons for refusal in a 12-week frailty trial
- Eligible patients were aged 65+ with a Fried Frailty Score ≥2











- We explored sociodemographic patterns of those who declined
- Zip code data was mapped to two social determinants of health: employment and income

### Results

**Table 1.** Demographic characteristics and reasons patients were not approached for the study Sex: N (%) Age: N (%) Race/Ethnicity: N (%) **Unknown** Male Female 65-74 75+ Non-White [n=33] [n=42] [n=18] [n=5] [n=32] [n=52] [n=13] **Uninterested-Declined Approach** 1 (3.22) 12 (38.7) 31 (47.7) 26 (83.9) 5 (16.1) 13 (41.9) 18 (58.1) 18 (58.1) 3 (30.0) Coordinator couldn't contact 3 (30.0) 10 (32.3) 9 (90.0) 1 (10.0) 7 (70.0) 7 (70.0) Lack of interest 1 (8.33) 4 (33.3) 8 (66.7) 4 (33.3) 7 (58.3) 1 (8.33) 11 (91.7) 3 (75.0) 0 (0.00) 4 (12.9) 3 (75.0) 1 (25.0) 1 (25.0) 4 (100.0) Time commitment 3 (60.0) 3 (60.0) 3 (60.0) Declined approach 5 (16.1) 2 (40.0) 2 (40.0) 2 (40.0) 10 (66.7) 4 (26.7) 14 (93.3) 1 (6.67) **Ineligible Per Oncologist** 5 (33.3) 15 (23.1) 11 (73.3) 6 (85.7) 7 (46.6) 6 (85.7) 1 (14.3) 1 (14.3) 6 (85.7) 1 (14.3) Too fit **Restarting Treatment** 3 (20.0) 2 (66.7) 1 (33.3) 0 (0.00) 3 (100) 3 (100) 0 (0.00) Recurrence/Metastatic Disease 3 (75.0) 0 (0.00) 4 (26.7) 3 (75.0) 1 (25.0) 1 (25.0) 4 (100) 0 (0.00) Cancer is past Stage III 1 (6.67) 0 (0.00) 1 (100) 1 (100) 0(0.00)1 (100) **Oncologist Doesn't Recommend** 4 (25.0) 8 (50.0) 16 (24.6) 12 (75.0) 8 (50.0) 9 (56.3) 5 (31.3) 2 (12.5) 5 (83.3) 4 (66.7) 1 (16.7) 1 (16.7) 5 (83.3) 1 (16.7) 1 (16.7) 1 (20.0) 2 (40.0) 3 (60.0) 4 (80.0) 3 (60.0) 2 (40.0) Memory/Cognitive Issues 5 (31.2) 1 (33.3) Too Frail 3 (18.8) 1 (33.3) 2 (66.7) 0 (0.00) 1 (33.3) 1 (33.3) Not a Good Candidate 2 (12.5) 2 (100.) 0 (0.00) 1 (50.0) 1 (50.0) 2 (100.) 0 (0.00) 3 (4.62) Lives too far away for study visits 2 (66.7) 1 (33.3) 3 (100.) 0 (0.00) 1 (33.3) 0 (0.00) 2 (66.7)

<u>Table 2.</u> Demographic characteristics and reasons patients were not consented onto study								
	Count (%) [n= 39]	Race/Ethnicity: N (%)		Sex: N (%)		Age: N (%)		
		White [n=34]	Non-White [n=5]	Male [n=15]	Female [n=19]	65-74 [n=23]	75+ [n=10]	Unknown [n=4]
Patient Uninterested	10 (25.6)	9 (90.0)	1 (10.0)	8 (80.0)	2 (20.0)	6 (60.0)	3 (30.0)	1 (10.0)
Too Fit per Patient	4 (10.3)	4 (100.)	0 (0.00)	1 (25.0)	3 (75.0)	4 (100)	0 (0.00)	
Time commitment	6 (7.69)	6 (100.)	0 (0.00)	1 (16.7)	4 (66.7)	3 (50.0)	1 (16.7)	2 (33.3)
No further procedures	4 (10.3)	3 (75.0)	1 (25.0)	2 (50.0)	2 (50.0)	3 (75.0)	1 (25.0)	
No Response	7 (17.9)	6 (85.7)	1 (14.3)	1 (14.3)	4 (57.1)	4 (57.1)	2 (28.6)	1 (14.3)
Other	8 (20.5)	6 (75.0)	2 (25.0)	2 (25.0)	4 (50.0)	3 (37.5)	3 (37.5)	
Caffeine Allergy	2 (25.0)	1 (2.56)	1 (2.56)	0 (0.00)	2 (100)	1 (50.0)	1 (50.0)	
Restarting	1 (12.5)	0 (0.00)	1 (100)	0 (0.00)	1 (100)	1 (100)	0 (0.00)	
Not Good Candidate	1 (12.5)	1 (100)	0 (0.00)	-	-	-	-	-
Lives too far	1 (12.5)	1 (100)	0 (0.00)	-	-	-	-	-
Only want Intervention	1 (12.5)	1 (100)	0 (0.00)	1 (100)	0 (0.00)	0 (0.00)	1 (100)	
Bad past experience	2 (25.0)	2 (100)	0 (0.00)	1 (50.0)	1 (50.0)	1 (50.0)	1 (50.0)	

# Conclusions

- Recruiting pre-frail/frail older cancer survivors into a nutraceutical trial is feasible
- Targeted recruitment strategies for underserved populations are needed

This work was supported by the University of Rochester CTSA award No. KL2TR001999 and the National Cancer Institute Grants Nos. UG1CA189961 and K01CA276257

#### Results





Figure 2: Average Annual Income of Approached Patients by Zip Code

**Post Intervention** 

n = 7



Post Intervention

n = 7

Figure 3: Comparison of the Distribution of Distance to Study Site: Approached vs Enrolled Patients

